Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial

RCT (n=162) found addition of FOLFOX to active symptom control improved overall survival (OS) in advanced biliary tract cancer after progression on cisplatin and gemcitabine (6.2 vs 5.3 months, HR for death 0.69, 95%CI 0.50-0.97, OS at 6 months = 50.6% vs 35.5%).

Source:

The Lancet Oncology